There are 2789 resources available
544P - A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Presenter: Eunjung Lee
Session: ePoster Display
545P - First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part
Presenter: Toshihiko Doi
Session: ePoster Display
547P - Early pharmacokinetic data from a phase I study of SQ3370 in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
Presenter: Vivek Subbiah
Session: ePoster Display
548P - Phase I study of oral GZ17-6.02 in patients with advanced solid tumors or lymphoma
Presenter: Alain Mita
Session: ePoster Display
549P - Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)
Presenter: Pavlina Spiliopoulou
Session: ePoster Display
550P - Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors
Presenter: Rishi Jain
Session: ePoster Display
551P - Chronological improvement in precision oncology implementation in Japan
Presenter: Keigo Komine
Session: ePoster Display
552P - Reasons of screening failure during the 28-day screening period in patients identified for inclusion in phase I trials and their outcome
Presenter: Iphigenie Korakis
Session: ePoster Display
553P - Innovative medicinal products and early access provision: Challenges and opportunities to improve access to care for oncology patients
Presenter: Andriy Krendyukov
Session: ePoster Display